# Outlook Therapeutics Inc. (OTLK)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $31M  
**Price:** $0.89 (+26.24%)

> Outlook Therapeutics Inc. is a late clinical-stage biopharmaceutical company specializing in ophthalmology. The company is focused on developing and commercializing ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab designed for the treatment of retinal diseases, particularly neovascular or “wet” age-related macular degeneration (wet AMD). Its lead product candidate seeks to provide a standardized, rigorously tested alternative to repackaged intravenous bevacizumab commonly used off-label in retinal care today. By concentrating on retina specialists and eye-care providers, Outlook Therapeutics aims to address important needs in dosing consistency, sterility, and regulatory oversight for anti-VEGF therapies used in vision-threatening conditions. Headquartered in Iselin, New Jersey, and founded in the United States, the company operates within the broader biotechnology and pharmaceutical markets, with a clear emphasis on improving treatment options for patients with serious retinal disorders.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1M | $57,205 | -$67M | -$62M | — |
| 2019 | $8M | — | -$36M | -$35M | — |
| 2018 | $3M | — | -$30M | -$30M | — |
| 2017 | $4M | — | -$36M | -$39M | — |
| 2016 | $3M | — | -$51M | -$53M | — |
| 2015 | $5M | — | -$47M | -$47M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $19M | $51M | -$32M | $8M | — |
| 2019 | $17M | $28M | -$16M | $8M | $1.08B |
| 2018 | $22M | $43M | -$26M | $2M | $164,967 |
| 2017 | $21M | $51M | -$34M | $3M | $203,710 |
| 2016 | $25M | $31M | -$5M | $2M | $3M |
| 2015 | $35M | $63M | -$54M | $9M | $3M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$52M | — | — |
| 2024 | -$69M | — | — |
| 2023 | -$43M | — | — |
| 2022 | -$57M | — | — |
| 2021 | -$54M | — | — |
| 2020 | -$32M | — | — |
| 2019 | -$32M | $437,307 | -$33M |
| 2018 | -$33M | $3M | -$36M |
| 2017 | -$16M | $292,086 | -$16M |

Source: [CompaniesByCap](https://companiesbycap.com/company/OTLK)